Latest news with #medicaldevices
Yahoo
2 hours ago
- Business
- Yahoo
Do You Believe in the Growth Trajectory of Boston Scientific Corporation (BSX)?
Parnassus Investments, an investment management company, released the 'Parnassus Growth Equity Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the Fund (Investor Shares) returned -8.59% (net of fees), outperforming the Russell 1000 Growth Index's -9.97% decline. In the first quarter, post-election optimism, driven by reduced regulation and a business-friendly environment, drifted away to concerns over fiscal and tariff uncertainties, which increased volatility and raised fears of a recession. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Parnassus Growth Equity Fund highlighted stocks such as Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) manufactures and markets medical devices for use in various interventional medical specialties. The one-month return of Boston Scientific Corporation (NYSE:BSX) was -0.65%, and its shares gained 35.80% of their value over the last 52 weeks. On June 26, 2025, Boston Scientific Corporation (NYSE:BSX) stock closed at $104.58 per share with a market capitalization of $154.721 billion. Parnassus Growth Equity Fund stated the following regarding Boston Scientific Corporation (NYSE:BSX) in its Q1 2025 investor letter: "Boston Scientific Corporation (NYSE:BSX), a medical device company, continued to report exceptionally strong growth led by its existing Watchman heart implant franchise and its recently launched Farapulse franchise. We expect the company's robust growth trajectory to continue in upcoming years, given the potential market for Farapulse, a promising treatment for atrial fibrillation." A surgeon examining a patient's brain in an operating room, paramedics nearby. Boston Scientific Corporation (NYSE:BSX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 108 hedge fund portfolios held Boston Scientific Corporation (NYSE:BSX) at the end of the first quarter, which was 96 in the previous quarter. Boston Scientific Corporation's (NYSE:BSX) reported revenue of $4.663 billion, reflecting a 20.9% growth compared to Q1 2024. While we acknowledge the potential of Boston Scientific Corporation (NYSE:BSX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Boston Scientific Corporation (NYSE:BSX) and shared the list of best stocks to invest in for a month. Boston Scientific Corporation (NYSE:BSX) contributed to Baron Health Care Fund's performance during Q1 2025. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
a day ago
- Business
- Yahoo
Hologic (HOLX) Surpasses Market Returns: Some Facts Worth Knowing
Hologic (HOLX) ended the recent trading session at $65.11, demonstrating a +1.31% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.8%. Elsewhere, the Dow gained 0.94%, while the tech-heavy Nasdaq added 0.97%. The medical device maker's stock has climbed by 0.88% in the past month, falling short of the Medical sector's gain of 3.12% and the S&P 500's gain of 5.12%. The investment community will be paying close attention to the earnings performance of Hologic in its upcoming release. The company's earnings per share (EPS) are projected to be $1.05, reflecting a 0.94% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $1.01 billion, indicating a 0.39% decrease compared to the same quarter of the previous year. HOLX's full-year Zacks Consensus Estimates are calling for earnings of $4.19 per share and revenue of $4.08 billion. These results would represent year-over-year changes of +2.7% and +1.16%, respectively. It is also important to note the recent changes to analyst estimates for Hologic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.11% downward. Right now, Hologic possesses a Zacks Rank of #4 (Sell). Looking at valuation, Hologic is presently trading at a Forward P/E ratio of 15.32. This expresses a discount compared to the average Forward P/E of 27.05 of its industry. It's also important to note that HOLX currently trades at a PEG ratio of 2.36. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Instruments industry currently had an average PEG ratio of 2.25 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 181, positioning it in the bottom 27% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow HOLX in the coming trading sessions, be sure to utilize Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Global Healthcare Technology Leader Selects Kneat
LIMERICK, Ireland, June 26, 2025 (GLOBE NEWSWIRE) -- inc. (TSX: KSI) (OTCQC: KSIOF), a leader in digitizing and automating validation and quality processes, is pleased to announce that a leading healthcare technology and diagnostics company ('the Company') has signed a multi-year Master Services Agreement with Kneat. The Company, which is headquartered in the United States, employs over 50,000 people and manufactures in more than a dozen countries worldwide. This manufacturer of medical technology, including medical devices and pharmaceutical diagnostics, will use the Kneat Gx platform initially to digitize its Commissioning, Qualification and Validation workflows for facilities, equipment and computer systems at several lead manufacturing sites. "After an extensive evaluation process this global leader selected Kneat to drive efficiency, quality and compliance through greater digitalization of their Validation processes,' said Eddie Ryan, Kneat CEO. 'I'm happy that Kneat will be supporting both new builds and ongoing operations where we are proven to deliver significant business value.' The steady pace of Kneat's strategic customer wins indicates that digital validation is progressively becoming the norm for life sciences companies. The State of Validation 2025 study also supports this trend. The total percentage of organizations surveyed that are either using or planning to use digital validation is now 93 percent, versus 86 percent in the 2024 study. The shift is unsurprising. Done right, digital validation delivers speed to market; trustworthy, scalable compliance; and a foundation to leverage integrated automation and AI-driven innovations in the future. About Kneat Kneat Solutions provides leading companies in highly regulated industries with unparalleled efficiency in validation and compliance through its digital validation platform Kneat Gx. As an industry leader in customer satisfaction, Kneat boasts an excellent record for implementation, powered by our user-friendly design, expert support, and on-demand training academy. Kneat Gx is an industry-leading digital validation platform that enables highly regulated companies to manage any validation discipline from end-to-end. Kneat Gx is fully ISO 9001 and ISO 27001 certified, fully validated, and 21 CFR Part 11/Annex 11 compliant. Multiple independent customer studies show up to 40% reduction in documentation cycle times, up to 20% faster speed to market, and a higher compliance standard. Cautionary and Forward-Looking Statements Except for the statements of historical fact contained herein, certain information presented constitutes 'forward-looking information' within the meaning of applicable Canadian securities laws. Such forward-looking information includes, but is not limited to, the relationship between Kneat and the customer, Kneat's business development activities, the use and implementation timelines of Kneat's software within the customer's validation processes, the ability and intent of the customer to scale the use of Kneat's software within the customer's organization, and the compliance of Kneat's platform under regulatory audit and inspection. While such forward-looking statements are expressed by Kneat, as stated in this release, in good faith and believed by Kneat to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. Kneat does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor's own risk. For more information visit Contact: Katie Keita, Kneat Investor RelationsP: + 1 902-450-2660 E: investors@ in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
How Is Solventum's Stock Performance Compared to Other Health Care Equipment Stocks?
Maplewood, Minnesota-based Solventum Corporation (SOLV) is a healthcare company that develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. With a market cap of $12.7 billion, it operates in four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Companies worth $10 billion or more are generally described as 'large-cap stocks,' and SOLV fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the medical instruments & supplies industry. With a global presence in over 90 countries and a workforce of approximately 22,000 employees, Solventum is poised to leverage its rich history of innovation and deep market penetration to navigate the healthcare industry. Super Micro Computer Just Struck a Deal with Ericsson. Should You Buy SMCI Stock Here? CEO Jensen Huang Just Sold Nvidia Stock. Should You? Cathie Wood Is Dumping Circle Stock. Should You? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Despite its strengths, the stock has plunged 12.7% from its 52-week high of $85.92 touched on Feb. 26. Over the past three months, SOLV stock has grown 1.1%, outperforming the SPDR S&P Health Care Equipment ETF's (XHE) 4.5% decline during the same time frame. SOLV stock has grown 13.5% on a YTD basis, outperforming XHE's 8.5% fall in 2025. Moreover, SOLV has surged 46.2% over the past 52 weeks, outperforming XHE's 2.6% decline. To confirm its bullish trend, SOLV has been trading above its 200-day and 50-day moving averages since early May. SOLV stock rose 1.7% following the release of its better-than-expected Q1 2025 results on May 8. The company's sales increased 2.7% year-over-year to $2.1 billion, driven by a growth in its MedSurg and HIS segments, and exceeded the Street's expectations. Moreover, its adjusted EPS decreased 35.6% from the prior-year quarter to $1.34, but surpassed the consensus estimates by 12.6%. Its rival, Align Technology, Inc. (ALGN), has declined 10.5% in 2025 and 21.3% over the past year, underperforming the stock. Among the 11 analysts covering the SOLV stock, the consensus rating is a 'Hold.' Its mean price target of $81.57 suggests an 8.8% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
Johnson & Johnson JNJ is one of the few large drug and medical device companies with a presence in both the pharmaceuticals as well as medical devices segments. J&J's medical devices segment, called MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues. Sales in the MedTech segment rose 4.1% on an operational basis in the first quarter of 2025, driven by new product uptake and commercial execution, and contributions from the recent acquisitions of Shockwave and Abiomed. However, sales in J&J's MedTech business continue to face headwinds in the Asia Pacific, particularly in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anticorruption campaign. VBP is a government-driven cost-containment effort in China. In the MedTech segment, recent acquisitions of Shockwave and Abiomed, as well as continued uptake of its new products, are likely to drive growth in 2025. However, J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. Competitive pressure is also hurting sales growth in some MedTech businesses, such as PFA ablation catheters in U.S. electrophysiology. JNJ expects continued impacts from VBP issues in China in 2025 as VBP expands across provinces and products. Nonetheless, sales are expected to be higher in the second half of 2025 than in the first half as the business moves past tougher first-quarter comps and new products gain momentum throughout 2025. However, tariff-related costs are expected to hurt profits in the MedTech segment J&J's MedTech unit faces strong competition from several major players in the medical device industry like Medtronic MDT, Abbott, Stryker SYK and Boston Scientific BSX. While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker Corporation is a global leader in medical technology, specializing in innovative solutions across surgical, neurotechnology, orthopedics and spine care. Boston Scientific markets products for cardiovascular, endoscopy, urology and neuromodulation. Abbott is known for its medical device products across cardiovascular, diagnostics, and diabetes care. J&J's shares have outperformed the industry year to date. The stock has risen 7.1% in the year-to-date period against a 0.4% decline of the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.12 forward earnings, lower than 14.92 for the industry. The stock is also trading below its five-year mean of 15.74. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.60 per share over the past 60 days, while that for 2026 has declined from $11.00 to $10.98 over the same timeframe. Image Source: Zacks Investment Research J&J has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
